Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections.

ABSTRACT: Adoptive cell transfer (ACT) has long been at the forefront of the battle with cancer that began last century with the therapeutic application of tumor-infiltrating lymphocytes (TILs) against melanoma. The development of novel ACT approaches led researchers and clinicians to highly efficient technologies based on genetically engineered T lymphocytes, with chimeric antigen receptor (CAR)-T cells as the most prominent example. CARs consist of an extracellular domain that represents the single-chain variable fragment (scFv) of a monoclonal antibody (mAb) responsible for target recognition and the intracellular domain, which was built from up to several signaling motifs that mediated T cell activation. The number of potential targets amenable for CAR-T cell therapy is expanding rapidly, which

SUBMITTER: Zmievskaya E 

PROVIDER: S-EPMC7827151 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature